Al Altomari, Chairman and CEO
Agile Therapeutics
Charlene Banard, Global Head of Technical Operations Cell & Gene Therapy Strategy, Innovation Pipeline and PMO
Novartis
Jeffrey Berkowitz, Board Member
H. Lundbeck A/S
Liz Bywater, Ph.D., President
Bywater Consulting Group
Ron Cohen, M.D., President & CEO
Acorda Therapeutics
Laurie Cooke, CEO
Healthcare Businesswomen's Association (HBA)
John Crowley, Chairman and CEO
Amicus Therapeutics
Rich Daly, Chief Operating Officer
Beyond Spring
Raúl Díaz, Animal Health Large Molecules Biopharm. Operations
MSD, Montes Claros, MG, Brazil
Tom Dilenge, President, Advocacy, Law & Public Policy Division
Biotechnology Innovation Organization
Joseph Ferra, CFO
Syros Pharmaceuticals
Anu Hans, VP, Strategic Initiatives
Janssen Supply Chain
Fred Hassan, Managing Director
Warburg Pincus
Paul Hastings, President and CEO
Nkarta Therapeutics
Axel Hoos, M.D., Ph.D., SVP Oncology R&D
GSK
John Hubbard, Ph.D., Emeritus Editorial Advisory Board Member
Life Science Leader
Mitchell Katz, Ph.D., Vice President, Development Operations
Ferring Pharmaceutical, Inc.
Mary Rose Keller, VP, Clinical Operations
Heron Therapeutics
Rachel King, CEO
GlycoMimetics
Suresh Kumar, Former EVP External Affairs
Sanofi
John LaMattina, Ph.D., Sr. Partner
PureTech Health
Jacks Lee, SVP global manufacturing and supply
Merck
Martin Lehr, CEO
Context Therapeutics
Sandy Macrae, Ph.D., President & CEO
Sangamo Therapeutics
Ken Moch, Former President & CEO
Cognition Therapeutics
Bernard Munos, Founder
InnoThink Center for Research in Biomedical Innovation
Carol Nacy, Ph.D., CEO
Sequella
Francois Nader, M.D., Chairman of the Board
Acceleron Pharma
Julia Owens, Ph.D., President and CEO
Millendo Therapeutics
Sandra Poole, COO
Candel Therapeutics
Dennis Purcell, Founder & Sr. Advisor
Aisling Capital
David Pyott, Chairman of the Board
Bioniz Therapeutics
Chandra Ramanathan, Ph.D., MBA, VP & Head, East Coast Innovation Center
Bayer
Stephen Rapundalo, Ph.D., President & CEO
MichBio
Pamela Reilly Contag, Ph.D., Cofounder and CEO
BioEclipse Therapeutics
John Reynders, Ph.D., VP, R&D strategy, program management, and data sciences
Alexion
James Robinson, Emeritus Editorial Advisory Board Member
Life Science Leader
Tomasz Sablinski, M.D., Ph.D., co-founder and board member
Transparency Life Sciences
Chhaya Shah, SVP Technical Operations
Radius Health
Allan Shaw, Independent Consultant
Brandi Simpson, Former President and CEO
Navigen
Andrew Skibo, Emeritus Editorial Advisory Board Member, Life Science Leader
MedImmune / AstraZeneca
Jason Urban, Ph.D., Sr. Dir. Quality Risk Management
Alexion
Thomas Wiggans, Founder, CEO, Chairman
Dermira
Leslie Williams, Entrepreneur, Executive, Board Member, Mentor
ImmusanT

IN THIS MONTH'S ISSUE

  • Democratic House Passes Rx Price Controls Amid Pandemic

    During this COVID-19 crisis, government should be collaborating closely with industry to promote innovation that will save lives, improve health and bring back prosperity that can come with safely reopening the economy. Yet, it is astonishing that House Democrats have chosen the opposite path.

  • The Politicizing Of Healthcare Vs. Principled Public Health Policy

    Politics must not drive population health. How do we safeguard against October surprises and ensure that announcements on drug and vaccine developments and approvals are driven by science and not politics?

  • Trends In Bioprocessing CDMO Selection

    Which CDMO characteristics do experienced outsourcers value the most when choosing a CDMO for biologic API production? Data from the past three iterations of ISR’s Bioprocessing Market Trends and Outsourcing Dynamics show the top selection metrics remain cosnsistent despite some shifts in ranks over the years. Learn which attributes to focus on as a sponsor or CDMO.

  • Demystifying AI In Pharma

    AI is less about the tool than what it can do. Instead of thinking about AI as a smart machine or some theoretical statistical algorithm, think of it as a framework consisting of five other words starting with “A”: automated, assistive, analytical, accelerated, and augmented.

  • COVID-19's Effect On Life Science Litigation

    For life sciences companies trying to navigate pre-COVID-19 obligations in this new post-coronavirus world, there are contractual provisions, relevant legal doctrines, and realities of the judicial system that warrant careful consideration.

@LIFESCILEADER1

 EVENTS